Your browser doesn't support javascript.
loading
Reply to: appropriate dosing of burosumab in tumor-induced osteomalacia.
Crotti, C; Zucchi, F; Alfieri, C; Caporali, R; Varenna, M.
  • Crotti C; Department of Rheumatology, ASST-Pini-CTO, Milan, Italy.
  • Zucchi F; Department of Rheumatology, ASST-Pini-CTO, Milan, Italy.
  • Alfieri C; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Caporali R; Department of Nephrology, Dialysis and Renal Transplant, Foundation Ca' Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy.
  • Varenna M; Department of Rheumatology, ASST-Pini-CTO, Milan, Italy.
Osteoporos Int ; 34(2): 423-424, 2023 02.
Article en En | MEDLINE | ID: mdl-36454247
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Osteomalacia / Raquitismo Hipofosfatémico Familiar Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Osteomalacia / Raquitismo Hipofosfatémico Familiar Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article